文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

超低剂量利妥昔单抗治疗类风湿关节炎:随机对照试验研究方案

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2017-08-30

REDO为研究者发起的6个月实用性双盲随机对照非劣效性试验,纳入140例既往利妥昔单抗诱导后达低疾病活动度、再治疗时DAS28CRP<3.5的类风湿关节炎患者,按1:2:2随机接受1×1000 mg、1×500 mg或1×200 mg利妥昔单抗。主要目标以基线至6个月DAS28CRP平均变化比较超低剂量与标准低剂量的非劣效性,非劣效界值0.6。

要点

  • 标准低剂量利妥昔单抗(2×500 mg或1×1000 mg)对活动性类风湿关节炎与注册剂量(2×1000 mg)同样有效。
  • 多项小型非对照研究提示更低剂量利妥昔单抗也可能带来良好治疗反应。
  • 超低剂量利妥昔单抗尚未在设计规范、样本量充分的对照试验中研究。

核心结论

  • 研究旨在检验超低剂量利妥昔单抗(1×500 mg或1×200 mg)相较标准低剂量(1×1000 mg)在再治疗类风湿关节炎患者中的非劣效性。

研究设计与样本

  • REDO为研究者发起的6个月实用性、双盲、随机对照非劣效性试验。
  • 纳入140例既往利妥昔单抗输注后达低疾病活动度(DAS28CRP<2.9)且再治疗时DAS28CRP<3.5的类风湿关节炎患者。
  • 按1:2:2随机分配至1×1000 mg、1×500 mg或1×200 mg利妥昔单抗组。

主要发现

  • 主要目标为比较基线至6个月DAS28CRP平均变化,非劣效界值为0.6。
  • 次要结局包括功能、生活质量、安全性、费用以及作为过程指标的药代动力学和药效学。

关键数值与推荐

  • 非劣效性界值为DAS28CRP平均变化0.6。
  • 再治疗时DAS28CRP<3.5且既往输注后DAS28CRP<2.9为入组条件。
  • 随机比例为1×1000 mg:1×500 mg:1×200 mg=1:2:2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A standard low-dosing schedule of rituximab (RTX; 2 × 500 mg or 1 × 1000 mg) is as effective for active rheumatoid arthritis (RA) as the registered dose (2 × 1000 mg). Moreover, several small uncontrolled studies suggest that even lower-dosed treatment with RTX also leads to good treatment response in patients with RA. Retreatment with such an 'ultra-low' dose RTX in patients who responded well to RTX induction treatment is of special interest, as long-term use of lower RTX doses may lead to shorter infusion duration, lower risk of adverse events and lower costs. However, the effect of ultra-low dose of RTX has not been investigated using a controlled trial of proper design and dimensions. METHODS/DESIGN: REDO is an investigator driven six-month pragmatic, double-blind, randomised controlled non-inferiority trial on the effects of ultra-low-dose RTX (1 × 500 or 1 × 200 mg) compared to standard low dose (1 × 1000 mg) in RA patients who are being retreated with RTX. A total of 140 RA patients, having reached low disease activity (DAS28CRP < 2.9) after the previous RTX infusion and DAS28CRP < 3.5 at moment of retreatment, are randomised in a ratio of 1:2:2 to 1 × 1000 mg, 1 × 500 mg or 1 × 200 mg. The primary objective is testing non-inferiority of the ultra-low-dose vs. standard low-dose RTX, by comparing mean change in DAS28CRP from baseline to six months to the non-inferiority margin of 0.6. Secondary outcomes over the same period are: function; quality of life; safety; costs; and pharmacokinetics and dynamics as process measures. DISCUSSION: This study protocol shares characteristics of both early dose finding trials as well as late pragmatic clinical studies. Several choices in the design of this trial are described and possible consequences for RA treatment and expected biosimilar introduction are discussed. TRIAL REGISTRATION: Dutch Trial Register, NTR6117 . Registered on 15 November 2016 (CMO NL57520.091.16 , 8 November 2016).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. den Broeder AA, Verhoef LM, Fransen J, et al. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials. 2017. PMID: 28854956. doi:10.1186/s13063-017-2134-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。